766539-39-3 Usage
Uses
Used in Pharmaceutical Industry:
Tert-Butyl 2-(2-methoxy-2-oxoethyl)morpholine-4-carboxylate is used as a precursor or intermediate for the synthesis of various pharmaceuticals. Its unique structure and functional groups enable the development of complex molecules with potential therapeutic properties, contributing to the discovery and production of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, Tert-Butyl 2-(2-methoxy-2-oxoethyl)morpholine-4-carboxylate serves as a key intermediate in the synthesis of agrochemicals. Its chemical properties allow for the creation of molecules with pesticidal or herbicidal activities, enhancing crop protection and yield.
Used in Research and Development:
Tert-Butyl 2-(2-methoxy-2-oxoethyl)morpholine-4-carboxylate is utilized as a versatile building block in the research and development of new chemical entities. Its specific properties and potential applications make it a valuable tool for chemists and researchers working on the design and synthesis of novel compounds with diverse applications in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 766539-39-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,6,6,5,3 and 9 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 766539-39:
(8*7)+(7*6)+(6*6)+(5*5)+(4*3)+(3*9)+(2*3)+(1*9)=213
213 % 10 = 3
So 766539-39-3 is a valid CAS Registry Number.
766539-39-3Relevant academic research and scientific papers
SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
-
Page/Page column 61-62, (2008/12/06)
This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
